[ Cirius Therapeutics raises $40M in Series A ]
Cirius Therapeutics has raised $40 million in Series A funding.
Founded in 2015, Cirius Therapeutics is a clinical-stage pharmaceutical company that focuses on developing therapies to treat liver diseases.
The company will use the proceeds to complete the ongoing Emminence trial, a Phase 2b study of MSDC-0602K, a next-generation insulin sensitizer, for the treatment of patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis.
|Founder / CEO||Bob Baltera|
|Investors||Frazier Healthcare Partners|
|Hopen Life Science Ventures|
|Adams Street Partners|
|Renaissance Venture Capital Fund|